There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > RENIN


Brief Information

Target Synonym:EC 3.4.23,REN,Renin,Angiotensinogenase,Angiotensin-Forming Enzyme,Renin Precursor, Renal,HNFJ2,EC:,EC
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
REN-M5222 Mouse Mouse RENIN Protein, His Tag
REN-H5221 Human Human RENIN Protein, His Tag

Synonym Name



Renin is also known as REN and angiotensinogenase, is a circulating enzyme that participates in the body's renin-angiotensin system (RAS), and plays an essential role in the elevation of arterial blood pressure and increased sodium retention by the kidney. Renin activates the renin-angiotensin system by cleaving angiotensinogen, produced by the liver, to yield angiotensin I, which is further converted into angiotensin II by ACE, the angiotensin-converting enzyme primarily within the capillaries of the lungs. Renin is secreted from kidney cells, which are activated via signaling from the macula densa, which responds to the rate of fluid flow through the distal tubule, by decreases in renal perfusion pressure (through stretch receptors in the vascular wall), and by sympathetic nervous stimulation, mainly through beta-1 receptor activation. Renin can bind to ATP6AP2, which results in a fourfold increase in the conversion of angiotensinogen to angiotensin I over that shown by soluble renin. In addition, renin binding results in phosphorylation of serine and tyrosine residues of ATP6AP2. The level of renin mRNA appears to be modulated by the binding of HADHB, HuR and CP1 to a regulatory region in the 3' UTR. An over-active renin-angiotension system leads to vasoconstriction and retention of sodium and water. These effects lead to hypertension. Therefore, renin inhibitors can be used for the treatment of hypertension.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Aliskiren Hemifumarate/Amlodipine Besilate/Hydrochlorothiazide Approved Novartis Pharma Ag Rasitrio, Amturnide United States Hypertension null 2010-12-21 Hypertension; Essential Hypertension Details
Aliskiren Hemifumarate/Hydrochlorothiazide Approved Novartis Pharma Ag Rasilez HCT, Tekturna HCT EU Essential Hypertension Noden Pharma Dac 2008-01-18 Hypertension; Essential Hypertension Details
Aliskiren Approved Details
Aliskiren Hemifumarate SPP-100; SPP-100A; SPP-100B; CGP-60536; CGP-60536B Approved Novartis Pharma Ag 锐思力, Enviage, Rasilez, Riprazo, Sprimeo, Tekturna Mainland China Essential Hypertension Noden Pharma Dac 2007-03-05 Heart Failure; Diabetes Mellitus, Type 2; Coronary Artery Disease; Hypertension; Diabetic macular oedema; Essential Hypertension; Cardiovascular Diseases; Kidney Failure, Chronic Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Imarikiren hydrochloride SCO-272; TAK-272 Phase 2 Clinical Takeda Pharmaceutical Co Ltd Kidney Diseases; Hypertension; Hepatic Insufficiency; Diabetic Nephropathies Details
SP-20104 (Sarfez Pharmaceuticals) SP-20104 Phase 2 Clinical 1 A Pharma Gmbh Glomerulosclerosis, Focal Segmental Details
SPH3127 SPH-3127 Phase 3 Clinical Mitsubishi Tanabe Pharma, Shanghai Pharmaceuticals Holding Co Ltd Hypertension; Essential Hypertension Details
IONIS-AGT-LRx IONISAGTLRx; ISIS-757456; ISISAGTLRx Phase 2 Clinical Ionis Pharmaceuticals Inc Heart Failure; Hypertension Details

This web search service is supported by Google Inc.